| 摘要 |
The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of β-catenin. The disclosure also relates to applications in the treatment of viral and infectious diseases, including infection by HIV, HPV, HBV, HSV, and bacteria including Mycobacterium, Shigella, and Listeria, and pharmaceutical compositions comprising such alpha helix mimetic β-catenin inhibitors. |
